Schering-Plough announces Pfizer closing
Schering-Plough has announced the successful closing of its previously announced transaction with Pfizer Animal Health, to divest certain animal health products from selected franchises in the European Economic Area to Pfizer.
With this announcement, Schering-Plough has now successfully completed all product divestments required by the commitments made to the European Commission in connection with its approval of its acquisition of Organon Biosciences in 2007.
Transaction an important step
“We are making good progress both globally and at the country level on our integration, and the closing of the transaction with Pfizer is another very important step in both that process, as well as fulfilling our acquisition-related commitments to the European Commission,” said Ruurd Stolp, President of Intervet/Schering-Plough
In Europe, Pfizer acquired products from the parasiticide, swine E. coli vaccine, ruminant clostridia vaccine, equine influenza vaccine, ruminant neonatal vaccine, anti-inflammatory, companion animal/insulin and companion animal/euthanasia, and rabies vaccine franchises of Intervet/Schering-Plough Animal Health. This agreement does not affect Intervet/Schering-Plough Animal Health’s marketing of these products in other global markets beyond Europe.